Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
Authors:
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (11) , 2081-2090
Abstract
The proliferation index in mantle cell lymphoma (MCL) has not been validated in the context of aggressive therapy regimens in the rituximab era. We assessed Ki67 and PIM1 (a cell cycle-related gene upregulated in blastoid MCL) expression by immunohistochemistry in a phase II study Cancer and Leukemia Group B 59909 of aggressive chemotherapy and rituximab followed by autologous stem cell transplantation plus rituximab in untreated MCL patients 35%) is an important independent prognostic marker in aggressively treated MCL in the rituximab era. PIM1 expression predicts poor outcome and, given its potential role as a therapeutic target, deserves further study.Keywords
This publication has 65 references indexed in Scilit:
- Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909Journal of Clinical Oncology, 2009
- PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformationNature Cell Biology, 2007
- Evidence that the Pim1 kinase gene is a direct target of HOXA9Blood, 2007
- Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression–Based Proliferation SignatureJournal of Clinical Oncology, 2007
- Mantle cell lymphoma: an update on managementAnnals of Oncology, 2006
- The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphomaBlood, 2006
- Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL NetworkBritish Journal of Haematology, 2005
- Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper siteFEBS Letters, 2004
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Resistance to Fas-mediated apoptosis: activation of Caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILPOncogene, 1998